High-dose vitamin B3 (niacin) may enhance immune activity and improve short-term disease control in glioblastoma when added to standard therapy, according to early preclinical studies.
Six months after receiving niacin in addition to standard treatments (surgery, radiation and chemotherapy), 82% of the patients showed no disease progression, compared to the typical 54%, according to the study's press release.
The study’s small sample size, short follow-up and lack of a randomized control group also posed limitations, the researchers acknowledged.
No comments :
Post a Comment
ANONYMOUS COMMENTS WILL NOT BE POSTED!
please use either your real name or a pseudonym.